Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1993 Jan;56(1):80–84. doi: 10.1136/jnnp.56.1.80

Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression.

P T Francis 1, M N Pangalos 1, P H Stephens 1, J R Bartlett 1, P K Bridges 1, A L Malizia 1, D Neary 1, A W Procter 1, D J Thomas 1, D M Bowen 1
PMCID: PMC1014771  PMID: 7679142

Abstract

Aspartic acid, 5-hydroxyindoleacetic acid, glutamic acid, homovanillic acid and 3-methoxy-4-hydroxyphenylethylene glycol was determined in samples of ventricular fluid from 82 subjects. Laminar distribution of the total number (Bmax value) of serotonin 1A receptors was determined on seven neurosurgical samples of neocortex. Apart from an association in a small subgroup of subjects between homovanillate concentration and corticosteroid medication, no complicating influences of treatment preceding operation were found. The content of the serotonin metabolite alone was significantly reduced in intractable depressive illness (bipolar and major depressive disorders) compared with neurological conditions subdivided into Alzheimer's disease, other dementias and other conditions. There was no other significant difference between these groups for the compounds measured. The total number of serotonin 1A receptors was highest in the superficial layers, being considerably higher than in the rat, irrespective of cortical layer. This part of the study indicated that these receptors are important for regulating activity of human corticocortical glutamatergic neurons. The results are discussed in relation to treating depression with serotonergic agents and targeting corticocortical glutamatergic neurons as well as acetylcholine in Alzheimer's disease.

Full text

PDF
81

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Björk L., Cornfield L. J., Nelson D. L., Hillver S. E., Andén N. E., Lewander T., Hacksell U. Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J Pharmacol Exp Ther. 1991 Jul 1;258(1):58–65. [PubMed] [Google Scholar]
  2. Bowen D. M., Najlerahim A., Procter A. W., Francis P. T., Murphy E. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9504–9508. doi: 10.1073/pnas.86.23.9504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bowen D. M. Treatment of Alzheimer's disease. Molecular pathology versus neurotransmitter-based therapy. Br J Psychiatry. 1990 Sep;157:327–330. doi: 10.1192/bjp.157.3.327. [DOI] [PubMed] [Google Scholar]
  4. Cheetham S. C., Crompton M. R., Katona C. L., Horton R. W. Brain 5-HT1 binding sites in depressed suicides. Psychopharmacology (Berl) 1990;102(4):544–548. doi: 10.1007/BF02247138. [DOI] [PubMed] [Google Scholar]
  5. Chessell I. P., Procter A. W., Francis P. T., Bowen D. M. D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res. 1991 Nov 29;565(2):345–348. doi: 10.1016/0006-8993(91)91668-q. [DOI] [PubMed] [Google Scholar]
  6. Cross A. J., Slater P. High affinity serotonin binding sites in human brain: a comparison of cerebral cortex and basal ganglia. J Neural Transm. 1989;76(3):211–219. doi: 10.1007/BF01260506. [DOI] [PubMed] [Google Scholar]
  7. Davies P. Therapy for Alzheimer's disease: choosing a target. Clin Neuropharmacol. 1991;14 (Suppl 1):S24–S33. doi: 10.1097/00002826-199114001-00005. [DOI] [PubMed] [Google Scholar]
  8. Francis P. T., Bowen D. M., Lowe S. L., Neary D., Mann D. M., Snowden J. S. Somatostatin content and release measured in cerebral biopsies from demented patients. J Neurol Sci. 1987 Mar;78(1):1–16. doi: 10.1016/0022-510x(87)90073-6. [DOI] [PubMed] [Google Scholar]
  9. Francis P. T., Pangalos M. N., Bowen D. M. Animal and drug modelling for Alzheimer synaptic pathology. Prog Neurobiol. 1992 Nov;39(5):517–545. doi: 10.1016/0301-0082(92)90005-y. [DOI] [PubMed] [Google Scholar]
  10. Francis P. T., Poynton A., Lowe S. L., Najlerahim A., Bridges P. K., Bartlett J. R., Procter A. W., Bruton C. J., Bowen D. M. Brain amino acid concentrations and Ca2+-dependent release in intractable depression assessed antemortem. Brain Res. 1989 Aug 14;494(2):315–324. doi: 10.1016/0006-8993(89)90600-8. [DOI] [PubMed] [Google Scholar]
  11. Halliwell J. V. M-current in human neocortical neurones. Neurosci Lett. 1986 Jun 6;67(1):1–6. doi: 10.1016/0304-3940(86)90198-9. [DOI] [PubMed] [Google Scholar]
  12. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991 Oct;12(10):383–388. doi: 10.1016/0165-6147(91)90609-v. [DOI] [PubMed] [Google Scholar]
  13. Liau L. M., Sleight A. J., Pitha J., Peroutka S. J. Characterization of a novel and potent 5-hydroxytryptamine1A receptor antagonist. Pharmacol Biochem Behav. 1991 Mar;38(3):555–559. doi: 10.1016/0091-3057(91)90013-r. [DOI] [PubMed] [Google Scholar]
  14. McCormick D. A., Williamson A. Convergence and divergence of neurotransmitter action in human cerebral cortex. Proc Natl Acad Sci U S A. 1989 Oct;86(20):8098–8102. doi: 10.1073/pnas.86.20.8098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Moir A. T., Ashcroft G. W., Crawford T. B., Eccleston D., Guldberg H. C. Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain. 1970;93(2):357–368. doi: 10.1093/brain/93.2.357. [DOI] [PubMed] [Google Scholar]
  16. Palmer A. M., Hutson P. H., Lowe S. L., Bowen D. M. Extracellular concentrations of aspartate and glutamate in rat neostriatum following chemical stimulation of frontal cortex. Exp Brain Res. 1989;75(3):659–663. doi: 10.1007/BF00249918. [DOI] [PubMed] [Google Scholar]
  17. Palmer A. M., Sims N. R., Bowen D. M., Neary D., Palo J., Wikstrom J., Davison A. N. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatry. 1984 May;47(5):481–484. doi: 10.1136/jnnp.47.5.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Palmer A. M., Stratmann G. C., Procter A. W., Bowen D. M. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol. 1988 Jun;23(6):616–620. doi: 10.1002/ana.410230616. [DOI] [PubMed] [Google Scholar]
  19. Pangalos M. N., Francis P. T., Pearson R. C., Middlemiss D. N., Bowen D. M. Destruction of a sub-population of cortical neurones by suicide transport of volkensin, a lectin from Adenia volkensii. J Neurosci Methods. 1991 Nov;40(1):17–29. doi: 10.1016/0165-0270(91)90113-e. [DOI] [PubMed] [Google Scholar]
  20. Pangalos M. N., Malizia A. L., Francis P. T., Lowe S. L., Bertolucci P. H., Procter A. W., Bridges P. K., Bartlett J. R., Bowen D. M. Effect of psychotropic drugs on excitatory amino acids in patients undergoing psychosurgery for depression. Br J Psychiatry. 1992 May;160:638–642. doi: 10.1192/bjp.160.5.638. [DOI] [PubMed] [Google Scholar]
  21. Pazos A., Palacios J. M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 1985 Nov 4;346(2):205–230. doi: 10.1016/0006-8993(85)90856-x. [DOI] [PubMed] [Google Scholar]
  22. Pazos A., Probst A., Palacios J. M. Serotonin receptors in the human brain--III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience. 1987 Apr;21(1):97–122. doi: 10.1016/0306-4522(87)90326-5. [DOI] [PubMed] [Google Scholar]
  23. Potter W. Z., Rudorfer M. V., Manji H. The pharmacologic treatment of depression. N Engl J Med. 1991 Aug 29;325(9):633–642. doi: 10.1056/NEJM199108293250907. [DOI] [PubMed] [Google Scholar]
  24. Procter A. W., Palmer A. M., Francis P. T., Lowe S. L., Neary D., Murphy E., Doshi R., Bowen D. M. Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J Neurochem. 1988 Mar;50(3):790–802. doi: 10.1111/j.1471-4159.1988.tb02983.x. [DOI] [PubMed] [Google Scholar]
  25. Procter A. W., Stirling J. M., Stratmann G. C., Cross A. J., Bowen D. M. Loss of glycine-dependent radioligand binding to the N-methyl-D-aspartate-phencyclidine receptor complex in patients with Alzheimer's disease. Neurosci Lett. 1989 Jun 5;101(1):62–66. doi: 10.1016/0304-3940(89)90441-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES